Use of anticonvulsive drugs during pregnancy and the risk of malformations in the newborn: A meta-analysis
Objective. To determine the risk, if any, of anticonvulsants use on the foetus with respect to major malformations. Materials and methods. MEDLINE, EMBASE, SCISEARCH and programs as ProQuest, HINARI y Ovid were searched for human studies. Studies that examined the effects of systematic exposure to a...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2003
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- spa
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/25085
- Acceso en línea:
- https://repository.urosario.edu.co/handle/10336/25085
- Palabra clave:
- Anticonvulsive agent
Carbamazepine
Felbamate
Gabapentin
Lamotrigine
Oxcarbazepine
Phenobarbital
Phenytoin
Valproic acid
Vigabatrin
Article
Cardiovascular malformation
Central nervous system malformation
Congenital malformation
Controlled study
Digestive system malformation
Embase
Epilepsy
Female
High risk patient
Human
Major clinical study
Medline
Pregnancy
Prenatal exposure
Scisearch
Skeleton malformation
Teratogenicity
Urinary tract malformation
Abnormalities
drug-induced
Anticonvulsants
Epilepsy
Female
Humans
Infant
newborn
Pregnancy
Pregnancy complications
Prenatal exposure delayed effects
Risk factors
Anticonvulsants
Epidemiology
Meta-analysis
Odds ratio
Pregnancy complications
Prenatal exposure delayed effects
- Rights
- License
- Bloqueado (Texto referencial)
Summary: | Objective. To determine the risk, if any, of anticonvulsants use on the foetus with respect to major malformations. Materials and methods. MEDLINE, EMBASE, SCISEARCH and programs as ProQuest, HINARI y Ovid were searched for human studies. Studies that examined the effects of systematic exposure to any anticonvulsant during pregnancy (any dose, any duration, indicated for any type of epilepsy) were eligible. Studies that assessed major malformations in the infants were eligible. Major malformations were defined using the criteria described by Holmes. The number of neonates exposed to anticonvulsants who did and did not exhibit major malformations, and the number of neonates not exposed to anticonvulsants who did and did not exhibit major malformations, were extracted in the form of 2 × 2 tables. The odds ratio (OR), relative risk and 95% confidence interval (CI) was calculated for each of the studies. Results. Ten cohort studies and four case-control studies were included. A total of 2,509 cases and 433,890 controls were included. Major malformations were found in 9,8% among the exposed children and 7,4% among the non exposed. (OR: 2,7; CI 95%: 2.062-3.641; p < 0.000). There was no evidence of an association between any anticonvulsant and a specific major malformation. Conclusions. The available epidemiological data support the hypothesis that anticonvulsants increase the risk of major malformations by an order of 2- to 3-fold. |
---|